Aptinyx

Aptinyx EBIT Margin

Delisted

The EBIT Margin (Operating Margin) of Aptinyx (APTX) as of Oct 23, 2026 is -7,453.40 %. In the previous year, EBIT Margin (Operating Margin) was -3,245.84 % — a change of 129.63% (lower).

EBIT Margin

-7,453.40 %

YoY

129.63%

Last updated:

EBIT Margin (Operating Margin) of Aptinyx is 2021 -7,453.40 % . EBIT Margin (Operating Margin) of Aptinyx was 2020 -3,245.84 % . It decreases by 129.63% lower compared to the previous year.

For Aptinyx, the operating (EBIT) margin of -7,453.4% is down versus -649.6% a few years ago.

The Aptinyx EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2016
-180.93 USD
Jan 1, 2017
-649.60 USD
Jan 1, 2018
-834.93 USD
Jan 1, 2019
-1,624.78 USD
Jan 1, 2020
-3,245.84 USD
Jan 1, 2021
-7,453.40 USD
The Aptinyx EBIT Margin history
YEAREBIT MarginYoY
-7,453.40 %+129.63%
-3,245.84 %+99.77%
-1,624.78 %+94.60%
-834.93 %+28.53%
-649.60 %+259.03%
-180.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptinyx Stock analysis

What does Aptinyx do? Aptinyx Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of neurological diseases. The company was founded in 2015 in Evanston, Illinois, USA, and has since achieved an impressive track record in researching and developing innovative therapies. The history of Aptinyx Inc begins with a group of experienced scientists and researchers who came together to push the boundaries of neuroscience research and discover new treatment options for people with brain disorders. The company is based on the belief that the human brain is a fascinating and complex entity that still holds many secrets. The company is committed to improving human well-being through innovative neurotherapeutic products and services. Aptinyx Inc's business model focuses on the research, development, and commercialization of novel therapeutic treatments for neurological diseases. The company closely collaborates with leading academic institutions and facilities to leverage the best research findings and methods. The company has a strong scientific foundation led by an experienced team of researchers and developers working on innovative biomarker and therapy strategies. Aptinyx Inc has focused on the development of neuromodulators and neuroprotectants to treat neurological diseases, including pain disorders, peripheral neuropathies, neuropathic pain, Parkinson's disease, post-traumatic stress disorder (PTSD), and other central nervous system disorders. Aptinyx Inc's products are based on a comprehensive understanding of the fundamentals of the nervous system and how it functions. The company offers a variety of products and services, including novel therapeutics for the treatment of pain, neuropathy, and other neurological diseases. These products are based on the utilization of Aptinyx's proprietary technologies to selectively modulate specific cell types and signaling pathways in the nervous system. The products and services of Aptinyx Inc have been regulated by leading health authorities in the US and Europe. Aptinyx Inc has two main divisions of products: the first focus is on the development of neuromodulators that specifically alleviate pain and modulate the brain. The second focus is on the development of neuroprotectants that help protect neurons and reduce inflammation in the nervous system. These two divisions are closely interconnected as they are based on a common platform grounded in the exploration of novel biomarkers and therapeutic targets. The products of Aptinyx Inc are designed for both pain relief and improvement of neural functions. Additionally, these products aim to enhance patient experience and quality of life. The company consistently collaborates with potential partners and experts to develop products tailored to the needs of patients and healthcare providers. Overall, Aptinyx Inc has revolutionized the world of neuroscience by exploring and developing innovative solutions for neurological diseases. The company has achieved an impressive track record by utilizing its scientific expertise and groundbreaking technologies to set new trends in neuroscience research and therapeutics. In summary, Aptinyx Inc has developed a unique approach to the development of neuromodulators and neuroprotectants based on a deep understanding of the structure and function of the nervous system. The products and services of the company have the potential to play a significant role in improving the quality of life for patients with neurological diseases. Aptinyx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aptinyx stock

EBIT Margin (Operating Margin) of Aptinyx is -7,453.40 % in 2021.

EBIT Margin (Operating Margin) of Aptinyx changed from -3,245.84 % to -7,453.40 %, representing a 129.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Aptinyx since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Aptinyx with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Aptinyx

All Key Metrics — Aptinyx